Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Cholangiocarcinoma 10Acrocephalosyndactylia 6Carcinoma, Transitional Cell 5Neoplasm Metastasis 4Breast Neoplasms 4Gastrointestinal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Solid Tumor 2Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma 2Urinary Bladder Neoplasms 1Solid Tumor, Miscellaneous 1Sarcoma 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Locally Advanced Unresectable Gastric Cancer 1Liposarcoma 1Leukemia, Myeloid, Acute 1

Interventions

Rituximab 161Cyclophosphamide 142fludarabine phosphate 89Peripheral Blood Stem Cell Transplantation 81Filgrastim 59Mycophenolic Acid 58Whole-Body Irradiation 53Cyclosporine 53Radiotherapy 52Lenalidomide 47Busulfan 45Tacrolimus 44Etoposide 43Antilymphocyte Serum 41Melphalan 37Methotrexate 31fludarabine 30Bortezomib 30Prednisone 28Bendamustine Hydrochloride 28Cytarabine 24Cord Blood Stem Cell Transplantation 23obinutuzumab 22Vincristine 22Methylprednisolone 21Flow Cytometry 21ibrutinib 19venetoclax 18sargramostim 17Granulocyte Colony-Stimulating Factor 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × pemigatinib × Clear all
NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

University of Utah

Phase 2 Recruiting
27 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡